Macrophage migration and gene expression in response to tumor hypoxia - PubMed (original) (raw)
Review
. 2005 Dec 10;117(5):701-8.
doi: 10.1002/ijc.21422.
Affiliations
- PMID: 16106399
- DOI: 10.1002/ijc.21422
Review
Macrophage migration and gene expression in response to tumor hypoxia
Craig Murdoch et al. Int J Cancer. 2005.
Abstract
Monocytes are recruited into tumors from the circulation along defined chemotactic gradients and they then differentiate into tumor-associated macrophages (TAMs). Recent evidence has shown that large numbers of TAMs are attracted to and retained in avascular and necrotic areas, where they are exposed to tumor hypoxia. At these sites, TAMs appear to undergo marked phenotypic changes with activation of hypoxia-inducible transcription factors, dramatically upregulating the expression of a large number of genes encoding mitogenic, proangiogenic and prometastatic cytokines and enzymes. As a consequence, high TAMs density has been correlated with increased tumor growth and angiogenesis in various tumor types. Since hypoxia is a hallmark feature of malignant tumors and hypoxic tumor cells are relatively resistant to radio- and chemotherapy, these areas have become a target for novel forms of anticancer therapy. These include hypoxia-targeted gene therapy in which macrophages are armed with therapeutic genes that are activated by hypoxia-responsive promoter elements. This restricts transgene expression to hypoxic areas, where the gene product is then released and acts on neighboring hypoxic tumor cells or proliferating blood vessels. In this way, the responses of macrophages to tumor hypoxia can be exploited to deliver potent antitumor agents to these poorly vascularized, and thus largely inaccessible, areas of tumors.
Copyright 2005 Wiley-Liss, Inc
Similar articles
- Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues.
Murdoch C, Giannoudis A, Lewis CE. Murdoch C, et al. Blood. 2004 Oct 15;104(8):2224-34. doi: 10.1182/blood-2004-03-1109. Epub 2004 Jul 1. Blood. 2004. PMID: 15231578 Review. - Monocytes and dendritic cells in a hypoxic environment: Spotlights on chemotaxis and migration.
Bosco MC, Puppo M, Blengio F, Fraone T, Cappello P, Giovarelli M, Varesio L. Bosco MC, et al. Immunobiology. 2008;213(9-10):733-49. doi: 10.1016/j.imbio.2008.07.031. Epub 2008 Sep 21. Immunobiology. 2008. PMID: 18926289 Review. - Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy.
Burke B, Tang N, Corke KP, Tazzyman D, Ameri K, Wells M, Lewis CE. Burke B, et al. J Pathol. 2002 Feb;196(2):204-12. doi: 10.1002/path.1029. J Pathol. 2002. PMID: 11793372 - Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors.
Kes MMG, Van den Bossche J, Griffioen AW, Huijbers EJM. Kes MMG, et al. Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188427. doi: 10.1016/j.bbcan.2020.188427. Epub 2020 Sep 20. Biochim Biophys Acta Rev Cancer. 2020. PMID: 32961257 Review. - Mathematical modeling predicts synergistic antitumor effects of combining a macrophage-based, hypoxia-targeted gene therapy with chemotherapy.
Owen MR, Stamper IJ, Muthana M, Richardson GW, Dobson J, Lewis CE, Byrne HM. Owen MR, et al. Cancer Res. 2011 Apr 15;71(8):2826-37. doi: 10.1158/0008-5472.CAN-10-2834. Epub 2011 Mar 1. Cancer Res. 2011. PMID: 21363914 Free PMC article.
Cited by
- HIF1α epigenetically repressed macrophages via CRISPR/Cas9-EZH2 system for enhanced cancer immunotherapy.
Dong Y, Zhang S, Gao X, Yin D, Wang T, Li Z, Wan Z, Wei M, Luo Y, Yang G, Liu L. Dong Y, et al. Bioact Mater. 2021 Feb 20;6(9):2870-2880. doi: 10.1016/j.bioactmat.2021.02.008. eCollection 2021 Sep. Bioact Mater. 2021. PMID: 33718668 Free PMC article. - Hypoxia and its impact on the tumour microenvironment of gastroesophageal cancers.
King R, Hayes C, Donohoe CL, Dunne MR, Davern M, Donlon NE. King R, et al. World J Gastrointest Oncol. 2021 May 15;13(5):312-331. doi: 10.4251/wjgo.v13.i5.312. World J Gastrointest Oncol. 2021. PMID: 34040696 Free PMC article. Review. - Engineering the Tumor Immune Microenvironment through Minimally Invasive Interventions.
Pal K, Sheth RA. Pal K, et al. Cancers (Basel). 2022 Dec 29;15(1):196. doi: 10.3390/cancers15010196. Cancers (Basel). 2022. PMID: 36612192 Free PMC article. Review. - Activated HIF1α of tumor cells promotes chemoresistance development via recruiting GDF15-producing tumor-associated macrophages in gastric cancer.
Yu S, Li Q, Yu Y, Cui Y, Li W, Liu T, Liu F. Yu S, et al. Cancer Immunol Immunother. 2020 Oct;69(10):1973-1987. doi: 10.1007/s00262-020-02598-5. Epub 2020 May 9. Cancer Immunol Immunother. 2020. PMID: 32388677 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials